.TEXTMersana Therapeutics, a biopharmaceutical company developing its Fleximer antibody-drug conjugate (ADC) platform, announced the creation of a Scientific Advisory Board (SAB) comprised of five professionals in the fields of oncology and antibody therapeutics.
According to a release, the SAB will provide critical strategic and scientific insight as the company advances its pipeline of next- generation ADCs.
"We are honored to work with these esteemed scientists, gathering additional scientific perspectives that we can leverage in our pipeline and partnerships," said Nicholas Bacopoulos, Ph.D., President and Chief Executive Officer of Mersana. "The members' collective broad knowledge of our space is invaluable as we solidify our unique position to capitalize on ADC drug development opportunities and the industry's surging strategic interest in the field."
Mersana's SAB members, as described by the Company, include:
-Greg Adams, Ph.D., is an Associate Professor and a Co-Leader of the Developmental Therapeutics Program at the Fox Chase Cancer Center. Dr. Adams heads an active research group focused on developing engineered antibodies using phage display and knowledge- based (rational) design. His current research is focused on developing antibodies and antibody-drug conjugates for the treatment of breast and ovarian cancers, characterizing the properties required for efficient tumor-targeting by engineered antibody-based molecules and the detection of circulating tumor antigens using piezoelectric immuno-nanocantilevers. He graduated with a Ph.D. in Immunology from the University of California at Davis, where he researched preclinical tumor targeting with radiolabelled monoclonal antibodies, focusing on the interactions between the antibodies and receptors on the liver. Dr. Adams also serves on the scientific advisory boards of Symphogen, Viventia Biotech, Endo Health Solutions (Oncology Advisory Board), Avipep and Avid Biologics and has served in the past on the advisory boards of YM Biosciences, Arana Therapeutics, Absalus and Xerion Pharmaceuticals. Dr. Adams is a member of the Editorial Boards of Cancer Immunology Research, MAbs and Cancer Biotherapy Radiopharmaceuticals and recently rotated off of the editorial board of Cancer Research.
-David Colcher, Ph.D., is Deputy Director of the Division of Radioimmunotherapy, Director of the Investigational Radiopharmacy and Professor in the Department of Cancer Immunotherapeutics and Tumor Immunology at the City of Hope National Medical Center'sBeckman Research Institute in Duarte, Calif. Dr. Colcher has experience in the field of developing antibodies to tumor associated antigens. He holds a number of patents on antibodies reactive with human malignancies as well as radiolabelling methods, which have led to three products being approved by the FDA, including a blood test for a tumor biomarker, a radiolabelled antibody imaging agent and a radiolabelled antibody therapeutic. He has consulted for, or been on the Scientific Advisory Board of a number of companies including Neoprobe, Molecular Oncology, Sterling Drug, Centocor, Coulter Pharmaceutical and Corixa Corp. Dr. Colcher received his Ph.D. and M.Ph. from Columbia University and an S.B.L.S. in Life Sciences from the Massachusetts Institute of Technology.